http://dk.linkedin.com/in/htschambye
Employees: 11-50
Total raised: $154.5M
Founded date: 2011
Investors 9
Funding Rounds 2
| Date | Series | Amount | Investors |
| 02.10.2020 | - | $64M | Eir Ventur... |
| 18.11.2018 | Series C | $90.5M | Ysios Capi... |
Mentions in press and media 21
| Date | Title | Description |
| 26.08.2024 | Opna Bio Doses First Patient in Phase 1 Study in Multiple Myeloma with OPN-6602, an EP300/CBP Bromodomain Inhibitor | Appoints Axel Bolte, MBA, MSc, to Board Director and Stephanie Oestreich, PhD, MPA, to Board Observer SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–August 26, 2024– Opna Bio announced that it has dosed the first patient with OPN-6602, a poten... |
| 28.11.2022 | Planday CEO Christian Brondum agrees to join Denmark's SEED Capital. | With Ulla Brockenhuus-Schack expected to call time on 18 years as the MD of Denmark's visionary seed-stage VC fund, SEED Capital, in mid-2024, the team now has a replacement lined up. The CEO of a Danish big name startup, Christian Brøndum ... |
| 08.11.2021 | Galecto KOL Webinar Presentation | Galecto KOL Event GB1211: A Potential Treatment For Non-Small Cell Lung Cancer NOVEMBER, 2021 Forward-looking statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements,... |
| 04.11.2021 | Galecto Reports Third Quarter Operating and Financial Results | Announces clinical collaboration with Roche for first line NSCLC Remains on track with clinical data milestone timing BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on ... |
| 09.06.2021 | Galecto Expert Perspectives: Myelofibrosis Treatment Landscape Current and Potential Future Treatments Presentation | Galecto Expert Perspectives: Myelofibrosis Treatment Landscape Current and Potential Future Treatments featuring Srdan Verstovsek, M.D., Ph.D. June 9, 2021 Forward-looking statements This presentation contains forward-looking statements tha... |
| 25.03.2021 | French biotech company Step Pharma raises €35 million in Series B | Step Pharma, a Paris based biotech company, announced on 24th March 2021 that it has raised €35 million in its Series B funding round. The round was led by Sunstone Life Science Ventures and Hadean Ventures, along with participation from Ku... |
| 11.12.2020 | GALECTO, INC. Galecto Reports Third Quarter 2020 Operating & Financial Results and Provides a Corporate Update | Successfully completed listing on US Nasdaq and raised over $150 million during recent IPO and preceding crossover round Funds to support preparations for potential EU conditional approval of GB0139 in IPF and multiple new Phase 2 clinical ... |
| 12.11.2020 | Ysios Capital anuncia la salida a bolsa en el NASDAQ de su participada Galecto, Inc | 12/11/2020 Nota de prensa YSIOS CAPITAL ANUNCIA LA SALIDA A BOLSA EN EL NASDAQ DE SU COMPAÑÍA PARTICIPADA GALECTO, INC. Ysios Capital, gestora española de capital riesgo (venture capital) líder en inversiones en el sector biotecnológico,... |
| 30.10.2020 | HBM-backed Galecto raises USD 85 million in Nasdaq IPO | Galecto (Nasdaq: GLTO), a privately held company in the portfolio of HBM Healthcare Investments, completed its intended IPO. The company placed 5.67 million new shares at a price of USD 15.00 per share, raising USD 85 million in new capital... |
| 29.09.2020 | Galecto Raises US$64M in Funding | Galecto, Inc., a Copenhagen, Denmark- and US-based biotechnology company focused on the development of novel treatments for fibrosis and cancer, completed a USD 64m equity financing. The round was led by Soleus Capital and co-led by Eir Ven... |
Show more